Eli Lilly and Company has taken the lead in in the manufacturing of tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant ability to improve glycemic control and reduce the risk of cardiovascular disease. The sophisticated synthesis of tirzepatide utilizes a series of pr